
        <!DOCTYPE html>
        <html>
        <head>
            <title>IDEAYA Biosciences Inc. (IDYA) - Articles</title>
            <meta name="viewport" content="width=device-width, initial-scale=1.0">
            <style>
                :root {
                    --primary-color: #000000;
                    --secondary-color: #666666;
                    --accent-color: #d5001c;
                    --text-color: #2c3e50;
                    --border-color: #e0e0e0;
                    --hover-color: #f8f9fa;
                }
                
                body { 
                    font-family: "Porsche Next", "Segoe UI", Arial, sans-serif;
                    margin: 0;
                    padding: 0;
                    color: var(--text-color);
                    background-color: #f5f6fa;
                    line-height: 1.6;
                }
                
                .header {
                    background: linear-gradient(135deg, #000 0%, #1a1a1a 100%);
                    padding: 25px 0;
                    box-shadow: 0 2px 10px rgba(0,0,0,0.2);
                    position: sticky;
                    top: 0;
                    z-index: 1000;
                    backdrop-filter: blur(10px);
                }
                
                .header::before {
                    content: '';
                    position: absolute;
                    top: 0;
                    left: 0;
                    right: 0;
                    bottom: 0;
                    background: radial-gradient(circle at 30% 50%, rgba(255,255,255,0.08) 0%, rgba(255,255,255,0) 70%);
                    pointer-events: none;
                }
                
                .header-content {
                    max-width: 1400px;
                    margin: 0 auto;
                    padding: 0 30px;
                    display: flex;
                    justify-content: space-between;
                    align-items: center;
                }
                
                .header-title {
                    font-size: 28px;
                    font-weight: 300;
                    color: #fff;
                    margin: 0;
                    letter-spacing: 1px;
                }
                
                .back-btn {
                    background: rgba(255,255,255,0.1);
                    border: 1px solid rgba(255,255,255,0.2);
                    padding: 10px 20px;
                    color: #fff;
                    text-decoration: none;
                    font-size: 14px;
                    border-radius: 4px;
                    transition: all 0.3s ease;
                    backdrop-filter: blur(5px);
                }
                
                .back-btn:hover {
                    background: rgba(255,255,255,0.2);
                    transform: translateY(-2px);
                }
                
                .container {
                    max-width: 1400px;
                    margin: 40px auto;
                    padding: 0 30px;
                }
                
                .stats-container {
                    display: grid;
                    grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
                    gap: 20px;
                    margin-bottom: 40px;
                }
                
                .stat-card {
                    background: #fff;
                    border-radius: 12px;
                    padding: 25px;
                    text-align: center;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: transform 0.3s ease;
                }
                
                .stat-card:hover {
                    transform: translateY(-5px);
                }
                
                .stat-value {
                    font-size: 32px;
                    font-weight: 300;
                    color: var(--primary-color);
                    margin-bottom: 10px;
                }
                
                .stat-label {
                    font-size: 14px;
                    color: var(--secondary-color);
                    text-transform: uppercase;
                    letter-spacing: 1px;
                }
                
                .articles-grid {
                    display: grid;
                    grid-template-columns: repeat(auto-fill, minmax(400px, 1fr));
                    gap: 30px;
                    margin-top: 40px;
                }
                
                .article-card {
                    background: #fff;
                    border-radius: 12px;
                    overflow: hidden;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: all 0.3s ease;
                }
                
                .article-card:hover {
                    transform: translateY(-5px);
                }
                
                .article-content {
                    padding: 25px;
                }
                
                .article-title {
                    font-size: 18px;
                    font-weight: 400;
                    margin: 0 0 15px;
                    line-height: 1.4;
                }
                
                .article-title a {
                    color: var(--primary-color);
                    text-decoration: none;
                    transition: color 0.2s ease;
                }
                
                .article-title a:hover {
                    color: var(--accent-color);
                }
                
                .article-meta {
                    display: flex;
                    align-items: center;
                    gap: 20px;
                    margin-bottom: 15px;
                    font-size: 14px;
                    color: var(--secondary-color);
                }
                
                .article-sentiment {
                    padding: 4px 12px;
                    border-radius: 20px;
                    font-weight: 500;
                    font-size: 14px;
                }
                
                .article-sentiment.positive {
                    background: rgba(40,167,69,0.1);
                    color: #28a745;
                }
                
                .article-sentiment.negative {
                    background: rgba(220,53,69,0.1);
                    color: #dc3545;
                }
                
                .article-sentiment.neutral {
                    background: rgba(108,117,125,0.1);
                    color: #6c757d;
                }
                
                .article-summary {
                    font-size: 14px;
                    color: var(--text-color);
                    line-height: 1.6;
                    margin-top: 15px;
                    opacity: 0.8;
                }
                
                @media (max-width: 768px) {
                    .header-content {
                        padding: 0 20px;
                    }
                    
                    .header-title {
                        font-size: 20px;
                    }
                    
                    .container {
                        padding: 0 20px;
                        margin: 20px auto;
                    }
                    
                    .articles-grid {
                        grid-template-columns: 1fr;
                        gap: 20px;
                    }
                    
                    .stat-card {
                        padding: 20px;
                    }
                    
                    .stat-value {
                        font-size: 28px;
                    }
                }
            </style>
        </head>
        <body>
            <div class="header">
                <div class="header-content">
                    <h1 class="header-title">IDEAYA Biosciences Inc. (IDYA)</h1>
                    <a href="sentiment_report_latest.html" class="back-btn">← Back to Dashboard</a>
                </div>
            </div>
            
            <div class="container">
                <div class="stats-container">
                    <div class="stat-card">
                        <div class="stat-value">8</div>
                        <div class="stat-label">Total Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">5</div>
                        <div class="stat-label">Positive Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">2</div>
                        <div class="stat-label">Negative Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">0.24</div>
                        <div class="stat-label">Average Sentiment</div>
                    </div>
                </div>
                
                <div class="articles-grid">
        
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=2a59a2de8509af9d9bbccc8d84d701a1008785a3d1cf887349a9f742e1a630b5" target="_blank" rel="noopener noreferrer">IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-04-10</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.85
                                </span>
                            </div>
                            <div class="article-summary">IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the initiation of a Phase 1/2 expansion in ...</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=e0fbc0d9bb9ca0a1646595e35a5f543b496467faa5acfe1476a76c83fcc203f7" target="_blank" rel="noopener noreferrer">Why Ideaya Biosciences Is Down Despite Many Positives</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-04-02</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment negative">
                                    -0.37
                                </span>
                            </div>
                            <div class="article-summary">Ideaya Biosciences, Inc.'s stock faces pressure from macroeconomic shifts and FDA policies, but remains a buy for savvy investors. Click for my IDYA update....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=62253b1ecfb3c08ea3559ee2562eb1a6c4817b53f5fe026840ba15c96d1bf03e" target="_blank" rel="noopener noreferrer">Hospitals Experience FOMO In Adopting Delcath's PHP Treatment</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-04-02</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment positive">
                                    0.23
                                </span>
                            </div>
                            <div class="article-summary">Delcath's Q4 sales exceeded expectations due to HEPZATO KIT adoption. Discover insights into its profitability, CHOPIN trial impact & 2025 sales forecast....</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=c6e7d9a37ca0afcc85a49fbb87105d8d6a857129d53f59ce7799f97195d3c36d" target="_blank" rel="noopener noreferrer">IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-04-01</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=4d3e0c03fe68fe0ea708915ff1cf1ecaf6c2672232296702dd00df18689ac735" target="_blank" rel="noopener noreferrer">IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-03-31</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.93
                                </span>
                            </div>
                            <div class="article-summary">IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that the U.S. Food and Drug Administ...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=ed1fb6eb1e287d7bdc00cfdcce940b63236c4ccc826cf382a0c9c251641d3b40" target="_blank" rel="noopener noreferrer">IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-03-28</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.34
                                </span>
                            </div>
                            <div class="article-summary">IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on March 27, 2025, the Compens...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=ce45e0446dbb8908245524b34bb15fbe24800f916af8334e660fc08e1e25134e" target="_blank" rel="noopener noreferrer">IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-03-26</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.50
                                </span>
                            </div>
                            <div class="article-summary">IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced the publication of abstracts for an oral presentation in the New Drugs on the Horizon series, an...</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=8f81827abb6ec00be306ef52a83e31acbe2c243bf3d6f7d992305822a81d2a8e" target="_blank" rel="noopener noreferrer">Invesco Health Care Fund Q4 2024 Commentary</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-03-20</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment negative">
                                    -0.56
                                </span>
                            </div>
                            <div class="article-summary">Stock selection in life science tools & services, pharmaceuticals and distributors detracted from relative performance, as did an overweight in health care facilities....</div>
                        </div>
                    </div>
            
                </div>
            </div>
        </body>
        </html>
        